

## Castleman's disease

### Identity

Other names      Angiofollicular lymph node hyperplasia

### Clinics and Pathology

Phenotype / cell stem origin    The disease appears to be polyclonal in origin in the majority of cases, however evidence for clonal expansion was documented in some cases, possibly representing transformation into non Hodgkin's lymphoma. In approximately 1/3 of the cases studied a monoclonal IgH rearrangement was documented. A minor T-cell clone, mostly in a polyclonal background, was also documented in some cases.

Epidemiology    The disease is very rare.

Clinics            The disease may present as a solitary mass frequently occurring in the mediastinum or as a systemic disorder (multicentric Castleman's disease) with diffuse adenopathies, systemic symptoms and recurrent infections. Splenomegaly, hepatomegaly and neurologic symptoms may occur frequently as is the case with autoimmune manifestations.

Pathology        There are two variants: the hyaline-vascular and the plasma cell subtype. In the former subtype there are shrunken germinal centres with concentric expansion of the mantle zones with eosinophils and hyalinization around the vessels; in the latter subtype an extensive infiltrate by plasma cells is seen in the interfollicular areas. Some patients may be infected by human herpesvirus-8 which may induce interleuchin-6 (IL6) overproduction. IL6 is believed to play an essential role in the pathogenesis of the disease.

The hyaline-vascular type is usually diagnosed in asymptomatic patients whereas systemic symptoms are present in the majority of patients with the plasma cell subtype. Patients with "multicentric" Castleman disease show histologic features consistent with the plasma cell subtype.

Treatment        The patients can be treated by surgical excision if the mass is localized. Steroid treatment is recommended in cases with disseminated disease and combination chemotherapy utilized for lymphoma must be reserved to unresponsive patients. Some patients with HIV associated Castleman's disease were successfully treated with the anti CD20 monoclonal antibody or with the antiviral agent ganciclovir targeting the HHV-8.

Prognosis        The prognosis varies greatly depending on the histologic type and disease presentation. If the disease is localized, surgery with or without radiotherapy may be curative. Those patients with multicentric disease who fail to respond to steroid treatment have a serious disease.

### Cytogenetics

Cytogenetics    Many of the cases so far studied showed a normal karyotype.

Morphological Occasional abnormalities were found in a few patients.

One case with the hyaline vascular type showed a t(1;6)(p11;p11), a del(7)(q21q22) and a del(8)(q12q22). In this patient no clonal expansion of lymphoid cells was present, suggesting that the clonal proliferation involved dysplastic stromal cells.

Another patient was shown to carry a clonal abnormality in CD21-positive follicular dendritic cells. Abnormal chromosomes in this patient were add(1)(q21), der(6)t(6;12)(q23;q15), add(7)(p22), -9, inv(9)p11q13, del(12)(q15).

One patient carried a t(7;14)(p22;q22).

## **Bibliography**

### **Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus.**

Hanson CA, Frizzera G, Patton DF, Peterson BA, McClain KL, Gajl-Peczalska KJ, Kersey JH.

Am J Pathol 1988; 131: 84-91.

Medline [2833104](#)

### **Atypical lymphoproliferative diseases.**

Greiner T, Armitage J, Gross T.

American Society of Hematology Educational book, 1992.

### **Chromosomal abnormalities in Castleman's disease with high levels of serum interleukin-6.**

Nakamura H, Nakaseko C, Ishii A, Kogure K, Kawano E, Hashimoto S, Nishimura M, Matsuura Y, Oh H, Yoshida S, et al.

Rinsho Ketsueki 1993; 34: 212-217.

Medline [8492420](#)

### **Molecular analysis of clonality in Castleman's disease.**

Soulier J, Grollet L, Oksenhendler E, Miclea JM, Cacoub P, Baruchel A, Brice P, Clauvel JP, d'Agay MF, Raphael M.

Blood 1995; 86: 1131-1138.

Medline [7620166](#)

### **A chromosomal abnormality in hyaline vascular Castleman's disease: evidence for clonal proliferation of dysplastic stromal cells.**

Pauwels P, Dal Cin P, Vlasveld LT, Aleva RM, van Erp WF, Jones D.

Am J Surg Pathol 2000; 24: 882-888.

Medline [10843293](#)

### **Atypical lymphoproliferative disorders.**

Frizzera G.

In Knowles DM (Ed) Neoplastic hemopathology IInd edition. Lippincott WW Philadelphia 2001; 569-622.

### **Lack of cytogenetic abnormalities in Castleman's disease.**

Menke DM, DeWald GW.

South Med J 2001; 94: 472-474.

Medline [11372793](#)

**Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis.**

Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, Hagemeyer A, Sciot R.  
Am J Surg Pathol 2002; 26: 662-669.

Medline [11979097](#)

**Remission of HHV-8 and HIV-associated multicentric Castleman's disease with ganciclovir treatment.**

Casper C, Nichols WG, Huang ML, Corey L, Wald A.  
Blood 2003 Nov 13 [Epub ahead of print]

Medline [14615380](#)

**A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.**

Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH.  
Ann Hematol 2003; 82: 766-768.

Medline [12898190](#)

**Rituximab therapy for HIV-associated Castleman disease.**

Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N.  
Blood 2003; 102: 2786-2788.

Medline [12842986](#)

## Contributor(s)

**Written** 12-2003 Antonio Cuneo, Gianluigi Castoldi

## Citation

*This paper should be referenced as such :*

**Cuneo A, Castoldi G** . Castleman's disease. Atlas Genet Cytogenet Oncol Haematol.  
December 2003 .

URL :

<http://www.infobiogen.fr/services/chromcancer/Anomalies/CastlemanID2123.html>

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

---